Please use this identifier to cite or link to this item:
http://earchive.tpu.ru/handle/11683/64872
Title: | Current outlook on radionuclide delivery systems: from design consideration to translation into clinics |
Authors: | Peltek, Aleksey Olekseevich Muslimov, Albert Radikovich Zyuzin, Mikhail Timin, Aleksandr Sergeevich |
Keywords: | nuclear medicine; diagnostic and therapeutic radionuclides; drug carrier systems; monoclonal antibodies; manoparticles; microspheres; radiopharmaceuticals; theranostics; multimodal imaging |
Issue Date: | 2020 |
Publisher: | Springer Nature |
Citation: | Current outlook on radionuclide delivery systems: from design consideration to translation into clinics / A. O. Peltek, A. R. Muslimov, M. V. Zyuzin, A. S. Timin // Journal of Nanobiotechnology. — 2020. — Vol. 17, iss. 1. — [90, 34 p.]. |
Abstract: | Radiopharmaceuticals have proven to be effective agents, since they can be successfully applied for both diagnostics and therapy. Effective application of relevant radionuclides in pre-clinical and clinical studies depends on the choice of a sufficient delivery platform. Herein, we provide a comprehensive review on the most relevant aspects in radionuclide delivery using the most employed carrier systems, including, (i) monoclonal antibodies and their fragments, (ii) organic and (iii) inorganic nanoparticles, and (iv) microspheres. This review offers an extensive analysis of radionuclide delivery systems, the approaches of their modification and radiolabeling strategies with the further prospects of their implementation in multimodal imaging and disease curing. Finally, the comparative outlook on the carriers and radionuclide choice, as well as on the targeting efficiency of the developed systems is discussed. |
URI: | http://earchive.tpu.ru/handle/11683/64872 |
Appears in Collections: | Репринты научных публикаций |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
reprint-nw-34916.pdf | 4,53 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.